Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Genpact Ltd ownership filing reports that Vanguard Capital Management beneficially owned 8,674,784 shares of Genpact common stock, representing 5.10% of the class as of 03/31/2026. The filing discloses sole voting power for 1,216,854 shares and sole dispositive power for 8,674,784 shares. The filing notes these holdings reflect securities managed by Vanguard Capital Management and certain affiliated Vanguard business divisions.
Vanguard Portfolio Management reports beneficial ownership of 8,705,834 shares of Genpact Ltd Common Stock, representing 5.12% of the class. The filing shows Vanguard Portfolio Management has sole dispositive power over 8,705,834 shares and sole voting power for 62,760 shares as reported on 03/31/2026.
The disclosure states these holdings reflect securities managed by Vanguard Portfolio Management LLC and affiliated business divisions, including shares held for Vanguard funds and client accounts.
Genpact Limited held its 2026 annual general meeting on April 23, 2026, where shareholders voted on director elections, executive pay and the auditor appointment. All ten board nominees were elected, each receiving over 128 million votes in favor, with broker non-votes of 9,589,913 for each director.
Shareholders approved, on a non-binding advisory basis, compensation for named executive officers, with 125,882,016 votes in favor, 9,847,642 against and 165,272 abstentions, plus 9,589,913 broker non-votes. They also approved appointing KPMG Assurance and Consulting Services LLP as independent registered public accounting firm for fiscal 2026, with 134,484,965 votes in favor, 10,944,301 against and 55,577 abstentions.
Hinshaw John M reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director John M. Hinshaw received an equity award in the form of restricted share units. He was granted 6,521 unvested RSUs, each entitling him to one common share in the future. Subject to his continued service, these RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this grant, he holds 8,855 common shares directly.
Morken CeCelia reported acquisition or exercise transactions in this Form 4 filing.
Genpact Ltd director CeCelia Morken received an equity grant in the form of restricted share units (RSUs). The award covers 6,521 common shares granted at no cash cost under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU entitles her to one common share at a future date, subject to continued service. The RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this grant, she directly holds 64,281 common shares.
Genpact LTD director Carol Lindstrom received an equity award of 6,521 common-share RSUs. The grant, priced at $0.00 per unit as compensation, increases her direct holdings to 27,706 common shares after the award. Each restricted share unit entitles her to one common share at a future date.
According to the award terms, all RSUs will fully vest on December 31, 2026, assuming she continues in service, and will be settled in common shares on December 31, 2027. This is a non-market, compensation-related acquisition rather than an open-market purchase.
Gangestad Nicholas C reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Nicholas C. Gangestad received an equity grant in the form of restricted share units. He was awarded 6,521 unvested RSUs, each representing one common share at a future date, increasing his direct holdings to 15,334 common shares after the award.
The RSUs were granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Subject to his continued service, the entire RSU award will vest on December 31, 2026 and will be settled in common shares on December 31, 2027, aligning his compensation further with long-term shareholder interests.
Subaiya Thimaya K. reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Subaiya Thimaya K. received a compensation grant of 6,521 unvested restricted share units (RSUs) of common shares at no cash cost. Each RSU represents one future Genpact common share. Subject to continued service, all RSUs will vest on December 31, 2026 and be settled in common shares on December 31, 2027. Following this award, the director holds 8,541 common shares directly, including the unvested RSUs reported in this filing.
Verdi Mark A reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Mark A. Verdi reported a compensation-related share grant. He received 6,521 unvested restricted share units (RSUs), with each RSU representing one common share granted at no cash cost. These RSUs fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this award, Verdi directly holds 71,526 common shares.
Genpact Limited director Brian Mark Stevens received an equity award in the form of restricted share units. He acquired 6,521 common shares at a price of $0.00 per share through a grant classified as a non-derivative award. Following this award, his direct holdings increased to 36,619 common shares.
The grant represents unvested restricted share units (RSUs) under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU entitles him to one common share. Subject to his continued service, the RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027.